Recently, EGFR- tyrosine kinase inhibitors (TKIs) and ALK inhibitors have been used widely in clinical settings as standard cancer therapies, and PTK-targeted therapies have demonstrated clinical success in the treatment of NSCLC [28,29]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.